Quick Snapshot
- Sun Pharma will announce Q1 FY27 (April–June 2026) results on Friday, July 31, 2026, followed by an earnings call at 6:30 pm IST the same day.
- Brokerages peg Q1 revenue between ₹15,280 crore and ₹15,364 crore, up 10–11% YoY, while net profit is projected to fall 7–11% YoY on margin pressure.
- India formulations are seen growing in double digits even as the US generics business stays largely flat.
- The stock touched a fresh 52-week high of ₹2,017.25 on July 30, a day ahead of results, taking market cap to nearly ₹4.80 lakh crore.
- Organon shareholders have cleared their side of the $11.75-billion acquisition; regulatory approvals and integration progress remain the key overhang beyond the headline print.
Sun Pharmaceutical Industries shares scaled a fresh 52-week high of ₹2,017.25 on the BSE on July 30, just one trading session before the country’s largest drugmaker opens its Q1 FY27 earnings. The stock closed the day at ₹2,000.75 on the BSE, up 0.55%, and at ₹2,001.10 on the NSE, up 0.56%, with the day’s ₹1,988–₹2,017 range brushing against the 52-week band on both exchanges. Market capitalisation stood at roughly ₹4.80 lakh crore heading into the print.
Check Live: SUN PHARMACEUTICAL INDUSTRIES Share Price Chart
Why This Quarter Matters
Sun Pharma enters FY27 coming off its strongest annual sales and profit on record, FY26 consolidated revenue of ₹58,220 crore and net profit of ₹11,479 crore, both the highest in the company’s history per its own investor disclosures (see the five-year trend below).
With the stock now at a fresh 52-week high, investor attention is shifting from the quarterly print itself toward whether specialty medicines, India formulations and the pending Organon integration can sustain this next leg of growth. A miss on margins or cautious FY27 commentary could trigger sharper-than-usual volatility precisely because expectations, and the valuation, are already stretched.
When Will Sun Pharma Announce Q1 FY27 Results?
Sun Pharma confirmed via an exchange filing that it will announce results for the quarter ended June 30, 2026, on Friday, July 31, 2026. Management will host an hour-long earnings call at 6:30 pm IST the same day, with dial-in access via +91 22 6629 0049 or +91 22 7194 5729, an audio webcast, and a transcript to follow on the company website.
In the run-up, the company has filed a string of Regulation 30 disclosures with exchanges, an analyst/investor meet intimation on July 14, press releases on July 15 and July 24, and a mandatory newspaper publication notice on July 28, a fairly routine sequence ahead of a quarterly print.
Check More: SUN PHARMACEUTICAL INDUSTRIES Options Chart
Q1 FY27 Estimates: What Brokerages Expect
Analysts expect decent topline growth for the April-June quarter, driven by strong domestic performance, even as the US generic business stays largely flat and EM/RoW markets deliver healthy growth on branded generics and innovative products. Margin pressure from elevated input costs is expected to weigh on profitability, with average estimates pointing to a 7-11% YoY profit decline.
| Brokerage | Est. Revenue (₹ Cr) | YoY Growth | Est. Net Profit (₹ Cr) | YoY Change |
|---|---|---|---|---|
| HDFC Securities | 15,364 | +11% | Not disclosed | EBITDA margin ~28.2% |
| Motilal Oswal (MOFSL) | ~15,280 | +10.8% | 2,785 | -7% |
| Kotak Institutional Equities (KIE) | 15,282 | +10.3% | 2,747 | -11.3% |
Source: Brokerage estimates compiled by Business Standard, July 29, 2026.
HDFC Securities attributes the muted US performance to the absence of gRevlimid contribution this year, while pegging India business growth at around 13% YoY. Kotak Institutional Equities expects gross margins to slip 60 basis points sequentially to 80.2%, with EBITDA growing 6% YoY even as margins contract 120 basis points to 28.2%.
Key Growth Drivers To Watch
Beyond the quarterly print, the performance of the recently-acquired Organon portfolio and progress on integrating the acquisition will be a key monitorable for analysts, according to MOFSL.
Sun Pharma agreed in April 2026 to acquire Organon in an all-cash deal valued at an enterprise value of $11.75 billion, its largest-ever acquisition, with Organon shareholders approving the transaction on July 24, 2026.
The deal, expected to close by early 2027 pending regulatory approvals, brings Organon’s women’s health, biosimilars and established-medicines portfolio, spread across more than 140 countries, into Sun Pharma’s fold, and is expected to lift combined annual revenue to roughly $12.4 billion.
Separately, the company’s specialty franchise in dermatology, ophthalmology and onco-dermatology continues to anchor its Global Innovative Medicines business, which the company says accounts for roughly a fifth of total sales.
Also Check: Nifty Pharma index constituents and performance
Key Risks And Overhangs
Margin pressure is the near-term drag analysts are flagging most consistently. HDFC Securities specifically cites cost escalation from higher input and freight costs as the reason it expects EBITDA margin to hold near 28.2%.
On the regulatory side, Sun Pharma received USFDA observations for its Dadra facility in June 2026, which management has characterised as largely procedural, with regulatory focus centred on remediation at both the Mohali and Dadra plants following recent inspections.
Any commentary on this during Friday’s call, alongside execution and financing details on the Organon deal, will likely matter as much to the stock as the headline revenue-profit print.
What Investors Should Watch
| Metric | Why It Matters |
|---|---|
| Revenue growth | Indicates underlying demand strength across geographies |
| EBITDA margin | Signals pricing power amid input-cost pressure |
| India formulation sales | Core domestic growth engine |
| US generics business | Read on the post-gRevlimid base and pricing environment |
| Specialty sales | High-margin growth lever for re-rating |
| Organon integration update | Execution signal on the year’s largest acquisition |
| FY27 guidance | Likely the biggest post-result stock trigger |
Sun Pharma’s Five-Year Financial Trend
| Fiscal Year | Consolidated Sales (₹ Cr) | Net Profit (₹ Cr) | EPS (₹) | India Sales (₹ Cr) |
|---|---|---|---|---|
| FY22 | 38,426 | 3,273 | 13.6 | 12,759 |
| FY23 | 43,279 | 8,474 | 35.3 | 13,603 |
| FY24 | 47,759 | 9,576 | 39.9 | 14,889 |
| FY25 | 52,041 | 10,929 | 45.6 | 16,923 |
| FY26 | 58,220 | 11,479 | 47.8 | 19,290 |
Source: Sun Pharma investor presentation, FY22–FY26 consolidated financials.
On the valuation side, the stock’s consolidated TTM EPS of ₹47.97 and consolidated PE of 41.71 line up closely with the FY26 EPS of ₹47.8 above, while ROE stands at 11.16% and price-to-book at 20.35, per BSE data. Day turnover on the counter stood at ₹24.20 crore on July 30.
Also Read:Â Cipla Q1 FY27 results coverage
NiftyTrader Desk View
| Stock | Key Technical Trigger | Trader View |
|---|---|---|
| Sun Pharma | Fresh 52-week high of ₹2,017 hit on July 30; immediate support near ₹1,989 (day-low/previous-close zone) | A sustained close above ₹2,017 would confirm a fresh breakout; a slip below ₹1,989 on a weak print could see the stock retest the ₹1,940–1,960 zone |
Source: BSE/NSE price data, July 30, 2026 close.
What To Watch After Results
Beyond revenue and profit, watch for management’s FY27 growth guidance, EBITDA margin trajectory, specialty sales momentum, any fresh update on the Dadra/Mohali USFDA status, and confirmation of regulatory progress on the Organon deal.
Track real-time institutional positioning ahead of the print on the NiftyTrader FII-DII Tracker.
Bottom Line
Sun Pharma heads into its Q1 FY27 results at a fresh 52-week high, with brokerages broadly aligned on low-double-digit revenue growth led by India formulations, offset by a YoY profit dip on margin pressure and a tough US comparison. The numbers themselves may matter less than management’s tone on Organon’s integration timeline and the regulatory status of its Dadra and Mohali plants.
Read Next: ITC Q1 FY27 Results on July 31: Cigarette Tax Impact May Weigh on Profit, FMCG Growth in Focus
FAQs
Q: When will Sun Pharma announce its Q1 FY27 results?
On Friday, July 31, 2026, followed by an earnings call at 6:30 pm IST.
Q: What do brokerages expect from Sun Pharma’s Q1 FY27 revenue?
Estimates range between roughly ₹15,280 crore and ₹15,364 crore, implying 10–11% YoY growth.
Q: Why could profit fall even as revenue rises?
HDFC Securities cites margin pressure from higher input and freight costs, plus a tough US comparison due to the absence of gRevlimid contribution this year.
Q: What is Sun Pharma’s current 52-week high?
₹2,017.25, touched on the BSE on July 30, 2026, a day ahead of results.
Q: Where does the Organon acquisition stand?
Organon shareholders approved the deal on July 24, 2026; it now awaits regulatory clearances ahead of an expected close in early 2027.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Stock market investments are subject to market risk; please consult a SEBI-registered investment advisor before making any investment decisions.
